Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 (2024)
- Authors:
- Santos, Yasmin Silva
- Gamon, Thaís Helena Martins
- Azevedo, Marcela Santiago Pacheco de
- Bielavsky, Mônica
- Darido, Maria Laura Goussain
- Oliveira, Danielle Bruna Leal de
- Souza, Edmarcia Elisa de
- Luvizotto, Maria Cecília Rui
- Ackerman, Hans Christian
- Carvalho, Leonardo José de Moura
- Epiphanio, Sabrina
- Wrenger, Carsten
- Durigon, Edison Luiz
- Marinho, Claudio Romero Farias
- Santos, Yasmin Silva
- USP affiliated authors: EPIPHANIO, SABRINA - FCF ; WRENGER, CARSTEN - ICB ; DURIGON, EDISON LUIZ - ICB ; MARINHO, CLAUDIO ROMERO FARIAS - ICB ; GAMON, THAÍS HELENA MARTINS - Interunidades em Biotecnologia ; BIELAVSKY, MONICA - FCF ; DARIDO, MARIA LAURA GOUSSAIN - ICB ; SOUZA, EDMARCIA ELISA DE - ICB ; Luvizotto, Maria Cecília Rui - ICB
- Unidades: FCF; ICB; Interunidades em Biotecnologia
- DOI: 10.3389/fphar.2024.1414406
- Subjects: PARASITOLOGIA; MICROBIOLOGIA; COVID-19; INIBIDORES DE ENZIMAS; DOENÇAS RESPIRATÓRIAS; ANGIOTENSINA II; SISTEMA RENINA-ANGIOTENSINA; ANTIVIRAIS; CAMUNDONGOS; MODELOS ANIMAIS DE DOENÇAS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Pharmacology
- ISSN: 1663-9812
- Volume/Número/Paginação/Ano: v. 15, art. 1414406
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
SANTOS, Yasmin Silva et al. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, v. 15, 2024Tradução . . Disponível em: https://doi.org/10.3389/fphar.2024.1414406. Acesso em: 10 fev. 2026. -
APA
Santos, Y. S., Gamon, T. H. M., Azevedo, M. S. P. de, Bielavsky, M., Darido, M. L. G., Oliveira, D. B. L. de, et al. (2024). Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19. Frontiers in Pharmacology, 15. doi:10.3389/fphar.2024.1414406 -
NLM
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2026 fev. 10 ] Available from: https://doi.org/10.3389/fphar.2024.1414406 -
Vancouver
Santos YS, Gamon THM, Azevedo MSP de, Bielavsky M, Darido MLG, Oliveira DBL de, Souza EE de, Luvizotto MCR, Ackerman HC, Carvalho LJ de M, Epiphanio S, Wrenger C, Durigon EL, Marinho CRF. Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19 [Internet]. Frontiers in Pharmacology. 2024 ; 15[citado 2026 fev. 10 ] Available from: https://doi.org/10.3389/fphar.2024.1414406 - Editorial: Emerging human viruses with pandemic potential: Diagnostics, pathogenesis, and therapeutics
- Pulmonary evaluation of humanized transgenic mice (K18 hACE2) treated with angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors
- Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease
- Plant-derived extracts and natural products with antiviral activity
- High target homology does not guarantee inhibition: aminothiazoles emerge as inhibitors of Plasmodium falciparum
- Targeting SUMOylation in plasmodium as a potential target for malaria therapy
- The continuous use of lisinopril in humanized transgenic mice infected with SARS-COV-2
- Angiotensin converting enzyme inhibition and/or angiotensin receptor blockade modulate cytokine profiles and improve clinical outcomes in experimental COVID-19 infection
- Anti-respiratory syncytial virus and anti-herpes simplex virus activity of chemically engineered sulfated fucans from Cystoseira indica
- Angiotensin-converting enzyme inhibition and/or angiotensin receptor blockade modulate cytokine profiles and improve clinical outcomes in experimental COVID-19 infection
Informações sobre o DOI: 10.3389/fphar.2024.1414406 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
